PKC-α regulates cardiac contractility and propensity toward heart failure

  title={PKC-$\alpha$ regulates cardiac contractility and propensity toward heart failure},
  author={Julian C. Braz and Kimberly N. Gregory and Anand Pathak and Wen Zhao and Bogachan Sahin and Raisa Klevitsky and Thomas F. Kimball and John N. Lorenz and Angus C. Nairn and Stephen B. Liggett and Ilona B{\'o}di and Su-yang Wang and Arnold M. Schwartz and Edward G. Lakatta and Anna A. Depaoli-Roach and Jeffrey Robbins and Timothy E. Hewett and James A Bibb and Margaret V Westfall and Evangelia G. Kranias and Jeffery D. Molkentin},
  journal={Nature Medicine},
The protein kinase C (PKC) family of serine/threonine kinases functions downstream of nearly all membrane-associated signal transduction pathways. Here we identify PKC-α as a fundamental regulator of cardiac contractility and Ca2+ handling in myocytes. Hearts of Prkca-deficient mice are hypercontractile, whereas those of transgenic mice overexpressing Prkca are hypocontractile. Adenoviral gene transfer of dominant-negative or wild-type PKC-α into cardiac myocytes enhances or reduces… 

Pharmacologic- and gene therapeutic-based inhibition of PKC α / β enhances cardiac contractility and attenuates heart failure

Acute inhibition of the conventional PKC isoforms with Ro-32-0432 or Ro-31-8220 significantly augmented cardiac contractility in vivo or in an isolated work performing heart preparation in wildtype mice, but not in PKC α deficient mice.

Pharmacological- and Gene Therapy–Based Inhibition of Protein Kinase Cα/β Enhances Cardiac Contractility and Attenuates Heart Failure

P pharmacological inhibition of PKCα, or the conventional PKC isoforms in general, may serve as a novel therapeutic strategy for enhancing cardiac contractility in certain stages of heart failure.

Protein Kinase Cα, but Not PKCβ or PKCγ, Regulates Contractility and Heart Failure Susceptibility: Implications for Ruboxistaurin as a Novel Therapeutic Approach

Protein kinase (PK)Cα, PKCβ, and PKCγ comprise the conventional PKC isoform subfamily, which is thought to regulate cardiac disease responsiveness. Indeed, mice lacking the gene for PKCα show

PKC-ing is believing: targeting protein kinase C in heart failure.

There are established and putative roles for PKCs in multiple physiological and pathological conditions, and specific interest in PKCα regulation of cardiac function stems from several important findings in small animal studies.

The role of protein kinase C-mediated phosphorylation of sarcomeric proteins in the heart—detrimental or beneficial?

The main focus of this review is the (patho)physiological impact of phosphorylation of sarcomeric proteins, myosin light chain-2, troponin I and T, desmin, myOSin binding protein-C, and titin by PKC.

Augmented Protein Kinase C-α–Induced Myofilament Protein Phosphorylation Contributes to Myofilament Dysfunction in Experimental Congestive Heart Failure

The results suggest that in end-stage congestive heart failure, the myofilament proteins exist in a hyperphosphorylated state attributable, in part, to increased activity and signaling of PKC-α.

Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging

Results indicate that phosphorylation of I-1 at Ser67 and Thr75 is associated with increased PP1 activity and depressed cardiomyocyte Ca2+-cycling, which manifests in geometrical alterations over the long term.

Agonist Activated PKCβII Translocation and Modulation of Cardiac Myocyte Contractile Function

Analysis showed downstream protein kinase D (PKD) phosphorylation and phosphatase activation are associated with the LY379196-sensitive contractile response, and patterns are consistent with bifurcated activation of downstream signaling activity by PKCβII.

PICOT increases cardiac contractility by inhibiting PKCζ activity.




PKCα regulates the hypertrophic growth of cardiomyocytes through extracellular signal–regulated kinase1/2 (ERK1/2)

Results implicate PKCα as a necessary mediator of cardiomyocyte hypertrophic growth, in part, through a ERK1/2-dependent signaling pathway.

Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart

It is determined that inhibition of calcineurin activity with cyclosporine prevented PKCα, θ, and JNK activation, but did not affect PKCε, β, λ, ERK1/2, or p38 activation.

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.

In failed human heart, PKC-beta1 and -beta2 expression and contribution to total PKC activity are significantly increased, which may signal a role for Ca2+-sensitive PKC isoforms in cardiac mechanisms involved in heart failure.

Type 1 Phosphatase, a Negative Regulator of Cardiac Function

PP1 is an important regulator of cardiac function, and inhibition of its activity may represent a novel therapeutic target in heart failure.

Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction.

The results suggest that the increased PKC activities in cardiac dysfunction due to MI may be associated with an increase in the expression of PKC-alpha, -beta, and -epsilon isozymes, and the improvement of heart function in the infarcted animals by imidapril may be due to partial prevention of changes in PKC activity and isozyme contents.

Protein kinase C isozymes and the regulation of diverse cell responses.

New ideas on mechanisms that regulate PKC activity, including the identification of a novel PKC kinase, 3-phosphoinositide-dependent kinase-1 (PDK-1), that regulates phosphorylation of PKC, have been advanced and opposing roles for selected isozymes in the same cell system have been defined.

Altered phosphatase activity in heart failure, influence on Ca2+ movement

PPs may play an important role in the etiology and/or symptoms of heart failure and subsequent dephosphorylation by of, e.g., PLB may explain the impaired relaxation of the human heart.

Protein Kinase C&agr; Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy

Abstract— The protein kinase C (PKC) family is implicated in cardiac hypertrophy, contractile failure, and &bgr;-adrenergic receptor (&bgr;AR) dysfunction. Herein, we describe the effects of gain-

Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy

Cardiomyocytes express several isoenzymes of protein kinase C (PKC), which as a group have been implicated in the induction of left ventricular hypertrophy (LVH) and its transition to heart failure.

Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts.

It is indicated that ablation of phospholamban is associated with downregulation of the ryanodine receptor to compensate for the increased Ca2+ content in the sarcoplasmic reticulum store and metabolic adaptations to establish a new energetic steady state to meet the increased ATP demand in the hyperdynamic phosphol amban-deficient hearts.